Navigation Links
GeoVax to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Date:8/26/2009

IV-1 vaccine would be expected to significantly decrease the prevalence of AIDS over time.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person become infected. GeoVax AIDS vaccines also may be effective as a therapeutic treatment (for people already infected with the HIV-1 virus).

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $17 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement

All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press rele
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
9. GeoVax to Present at the BIO CEO & Investor Conference 2009
10. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
11. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 SynGen Inc., a company that ... that harvest stem and progenitor cells from umbilical cord ... today that it has added three new members to ... Blood Business Units focus on product commercialization. ... its Vice President and Chief Financial Officer.  Chuck was ...
(Date:4/27/2015)... tru Shrimp™ Systems announced today that it has ... the exclusive worldwide rights to commercialize Tidal Basin™ technology, ... agreement for the patented technology, developed by world-renowned shrimp ... China, Taiwan, France, Germany, Italy, Spain, the Netherlands and ... from all over the world for our Tidal Basin™ ...
(Date:4/24/2015)... April 24, 2015 Top student social ... San Diego area universities, including UCSD and SDSU, will ... from prominent local, national and nonprofit companies for an ... 5th Annual Social Innovation Challenge 2015 . , ... social venture ideas addressing a diverse range of issues ...
(Date:4/24/2015)... DIEGO , April 24, 2015  Pfenex Inc. ... the development of biosimilar therapeutics including high value and ... its follow-on public offering of 6,000,000 shares of its ... $15.50 per share. Of the shares being offered, 2,610,000 ... shares are being offered by existing stockholders. Pfenex will ...
Breaking Biology Technology:SynGen Inc. Expands Its Management Team 2tru Shrimp™ Systems Acquires Global Patent for Tidal Basin™ Shrimp Production 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 3Pfenex Inc. Announces Pricing Of Follow-on Offering 2
... LA JOLLA, Calif., March 18 TorreyPines Therapeutics,Inc. ... initiated a Phase II study of,NGX267, a muscarinic ... to Sjogren,s syndrome., The company is conducting ... square design to evaluate,the safety, tolerability and efficacy ...
... NEOG ) announces the following Webcast:, What: Neogen ... EDT, Where: http://www.videonewswire.com/event.asp?id=46587 , How: ... the address above., ... are unable to participate during the live webcast, the call will,be archived ...
... - Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) ("Oncolytics") ... 7,344,711 entitled "Use of Adenoviruses Mutated in the,VA ... of treating,cancer using adenoviruses that are modified to ... Ras pathway., "This patent expands our adenovirus ...
Cached Biology Technology:TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent 2
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:4/2/2015)... Md. , April 2, 2015 At ... Salt Lake City , the American College ... of five new directors to its Board.  Members of ... the ACMG and for forming and advancing its policies ... medical genetics profession. "It,s an eventful time ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... LEDs may help reduce skin ... in Germany are describing a potential alternative to Botox ... scheduled for the November 5 issue of ACS, ... that high intensity visible light from light emitting diodes ...
... cleavage product, amyloid-b (Ab), builds up into fibrous plaques ... one specialized membrane microdomain to another to be cleaved, ... definitive evidence that Ab plaques are the direct cause ... support this. And working on this hypothesis, scientists are ...
... one step closer to finding a vaccine that better ... at Saint Louis University appears likely to offer significantly ... one in current use. "Not only was it ... better immune response, which suggests it will be more ...
Cached Biology News:American Chemical Society Weekly PressPac Oct. 15, 2008 2American Chemical Society Weekly PressPac Oct. 15, 2008 3American Chemical Society Weekly PressPac Oct. 15, 2008 4American Chemical Society Weekly PressPac Oct. 15, 2008 5American Chemical Society Weekly PressPac Oct. 15, 2008 6American Chemical Society Weekly PressPac Oct. 15, 2008 7American Chemical Society Weekly PressPac Oct. 15, 2008 8Research identifies type of vaccine that holds promise in protecting against TB 2
... on over 20 years of experience in ... Life Sciences, the Freedom EVO platform delivers ... according to future needs. Together with the ... is equipped to successfully operate genomics, proteomics, ...
... Use in any standard fixed-angle ... 16,000 g.,Spin- centrifuge tube filters ... within a centrifuge tube. They filter ... removal, HPLC sample preparation, removal of ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: polystyrene ...
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
Biology Products: